INCATE

📢 Great news for Phage Therapy: Singapore General Hospital successfully treated a patient with an antibiotic-resistant infection using phage therapy, marking a first in South-east Asia. Read here ➡️ https://lnkd.in/ek6sdW8C

📢 INCATE is on Bluesky - are we connected yet? At INCATE, strengthening connections and building strong networks is at the heart of our mission - and this platform feels like the perfect place to keep on growing! Let’s connect and keep the conversation going! ➡️ https://lnkd.in/eBapXZwV

INCATE is heading to #ESCMIDGlobal2025 in Vienna! We will be represented by our colleague Silke Alt, and we are looking forward to connecting with the AMR community. Will you be there? Let’s meet up! 📅 April 11–15 2025 📍 Messe Wien Exhibition & Congress Centre, Vienna Explore the programme ➡️ https://lnkd.in/ePeJWWfr

World Health Day 2025 | A Call to Action on Antibiotic Resistance On this World Health Day, we are reminded that health is a human right, not a privilege. But without effective antibiotics, even the most basic medical care is at risk. Antimicrobial resistance is one of the greatest global health threats of our time. It already claims over a million lives every year - and yet the pipeline for new antibiotics is small. Why? - Scientific challenges - Low return on investment - Complex regulatory and commercial landscapes This is where INCATE steps in. At INCATE, we are building a bridge between early-stage innovation and the support needed to bring new antibiotics to market. By connecting academia, industry, investors, and public health institutions, we help turn great science into real-world solutions. If we want a future where treatable infections stay treatable, we need to support the innovators working on the front lines of drug resistance. To all researchers, entrepreneurs, and partners tackling AMR: your work is more vital than ever!

Kicking off the week with fantastic news from our community! Arvalus Therapeutics has secured a €2.2M non-dilutive grant from the German Center for Infection Research (DZIF) — a major milestone that will support their progression into Phase 1 clinical trials for their innovative live biotherapeutic product (LBP). A spin-off from the Helmholtz Centre for Infection Research in Braunschweig, Arvalus is backed by several key funding initiatives, including Helmholtz Enterprise, DZIF, INCATE, and the Federal Ministry of Education and Research, Germany (BMBF). They fight severe infections by developing unique and safe Live Biotherapeutic Products (LBPs) based on years of ground-breaking top research. Huge congratulations to the Arvalus team — this is a big win, and a testament to your vision and dedication. Onward and upward! 

The weekend is finally here! Take this time to rest, recharge, and reset... and, Monday will be here before we know it! How was your week? (Thank you Twisted Doodles for the lovely cartoon!)

Could the key to face the antibiotic crisis lie in a completely new approach? Researchers from ETH Zürich, the University of Oxford, and the University of Basel have created a different strategy that combines vaccination with beneficial gut bacteria to combat Antimicrobial Resistance. By administering both a vaccine and genetically engineered E. coli strains that outcompete harmful bacteria in mice, their dual approach proved more effective than either method alone. Harnessing the natural competitive behavior of bacteria, this innovation offers a sustainable way to fight antibiotic resistance. Curious to learn more? Read full details here: Article ➡️ https://lnkd.in/gR9SzYJp Original publication ➡️ https://lnkd.in/g2-Wf3EK

A recent study in The Journal of Clinical Investigation explores bacteriophage therapy as a potential solution for multidrug-resistant (MDR) infections. The paper provides a comprehensive overview of current phage therapy technologies and therapeutic strategies. While phage therapy holds great promise, the study highlights the need for a structured drug development pipeline and sustained government support to drive its widespread adoption. We are looking forward to seeing how this research influences future advancements in combating antibiotic resistance! Read paper here ➡️ https://lnkd.in/gBg8irq6

The World Health Organization (WHO) has released its first-ever reports on the severe shortage of medicines and diagnostic tools for invasive fungal infections. This highlights the urgent need for innovation in research and development (R&D) to bridge these critical gaps. Fungal diseases are a growing public health threat, with common infections like Candida becoming increasingly resistant to treatment. Those most at risk include critically ill patients and individuals with weakened immune systems, such as people undergoing cancer treatment, living with HIV, or recovering from organ transplants. Now more than ever, collaborative efforts in R&D are essential to improve diagnosis and treatment options. Read report here ➡️ https://lnkd.in/exipeS47

More great news in the fight against AMR! The U.S. Food and Drug Administration has approved GSK's Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in women and adolescent girls aged 12 and older. Blujepa introduces a novel mechanism of action, marking the first new class of oral antibiotics for uUTIs in over 30 years. It targets common uropathogens like Escherichia coli and Staphylococcus saprophyticus, including strains resistant to existing treatments. Congratulations to GSK on this groundbreaking advancement in antibiotic therapy! Read all here ➡️ https://lnkd.in/ee7FKgnH